-
REAL-WORLD EFFECTIVENESS OF TEPOTINIB MONOTHERAPY (TEPOTINIB) VERSUS PEMBROLIZUMAB ± CHEMOTHERAPY (PEMBRO±CT) IN 1L FOR PATIENTS WITH MET EXON 14 SKIPPING ALTERATIONS IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN THE US
Aug 11, 2026, 17:16 PM -
A MULTI-COUNTRY PAYER AND HTA EXPERT SURVEY EXAMINING HOW ACCESS DECISION-MAKERS NAVIGATE INFORMATION OVERLOAD AND EVOLVING EVIDENCE SOURCES
Aug 11, 2026, 17:16 PM -
DOES INTERNATIONAL MIGRATION SHIFT HEALTHCARE SPENDING TOWARD FORMAL CARE? EVIDENCE FROM RURAL BANGLADESH
Aug 11, 2026, 17:16 PM -
DATA ACCESSIBILITY AND METHODOLOGICAL HETEROGENEITY IN ESTIMATING THE BURDEN OF RARE DISEASES ACROSS FOUR CENTRAL AND EASTERN EUROPEAN COUNTRIES: A CROSS-COUNTRY COMPARISON
Aug 11, 2026, 17:16 PM -
EXTERNAL VALIDATION OF DIABETIC RETINOPATHY RISK PREDICTION EQUATIONS IN TAIWANESE PATIENTS WITH TYPE 2 DIABETES
Aug 11, 2026, 17:16 PM -
FOREGONE HEALTH GAINS FROM PASKWIL-NEGATIVE ONCOLOGY DRUGS IN THE PALLIATIVE SETTING: A MODEL-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
TOTAL COST OF CARE ANALYSIS OF FIRST-LINE IMMUNO-ONCOLOGY THERAPIES FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A COLOMBIAN PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
VALUE SET PLAUSIBLE? EVIDENCE FROM RECENT FRENCH HTA APPRAISALS
Aug 11, 2026, 17:16 PM -
TOOLS FOR ASSESSING RISK OF BIAS IN REAL-WORLD EVIDENCE: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
COST-UTILITY OF ENOBOSARM VERSUS RESISTANCE EXERCISE TRAINING FOR SARCOPENIA IN US COMMUNITY DWELLING OLDER ADULTS. A DECISION ANALYTIC MODEL
Aug 11, 2026, 17:16 PM -
IDENTIFICATION AND VALIDATION OF OUTCOMES IMPORTANT TO BOTH PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND SPECIALIST CLINICIANS: A THREE-ROUND DELPHI METHODOLOGY STUDY
Aug 11, 2026, 17:16 PM -
MAXIMUM COST-EFFECTIVE PRICE OF SERPLULIMAB FOR FIRST-LINE EXTENSIVE-STAGE SMALL-CELL LUNG CANCER: A THRESHOLD ANALYSIS FOR THE PERUVIAN PRIVATE HEALTH SYSTEM
Aug 11, 2026, 17:16 PM -
ESTIMATING REAL-WORLD PERSISTENCE TO CARDIOMETABOLIC MEDICATION IN PEOPLE WITH TYPE 2 DIABETES TO INFORM AN EARLY HTA: A CAREPATH STUDY
Aug 11, 2026, 17:16 PM -
ASSESSING THE PUBLIC HEALTH IMPACT OF BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: QALY RESULTS FROM A BRAZILIAN PERSPECTIVE
Aug 11, 2026, 17:16 PM -
THE EMA ACCELERATED ASSESSMENT PROCEDURE AND ITS IMPLICATIONS FOR THE NATIONAL ITALIAN ACCESS PATHWAY
Aug 11, 2026, 17:16 PM -
DIRECT HEALTHCARE COST BURDEN OF POST-STROKE SPASTICITY IN GREECE
Aug 11, 2026, 17:16 PM -
LOW-COST FEATURE EXTRACTION FROM CLINICAL NOTES USING HUMMINGBIRD: ECOG PERFORMANCE STATUS OF LUNG CANCER PATIENTS
Aug 11, 2026, 17:16 PM -
GEOGRAPHIC VARIATION IN HOW PHYSICIANS CONCEPTUALISE, ASSESS AND ACT ON DISEASE ACTIVITY AND PROGRESSION IN MULTIPLE SCLEROSIS: A REAL-WORLD MULTI-COUNTRY SURVEY
Aug 11, 2026, 17:16 PM -
THE CURRENT STATUS OF SOCIAL CARE-RELATED QUALITY OF LIFE FOR PEOPLE WITH DISABILITIES IN JAPAN
Aug 11, 2026, 17:16 PM -
AI-DRIVEN ISPOR-SMDM VALIDATION OF AN EXCEL-BASED COST-EFFECTIVENESS MODEL
Aug 11, 2026, 17:16 PM
